Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$71.06−0.91 (-1.26%)
Close on Nov 17, 2026Market cap $476.97MP/E –Yield –
Monopar Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Monopar Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.18M. For fiscal 2025 it was -$12.20M. The highest annual figure on record is -$1.19M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.20M | – |
| FY2024 | Dec 31, 2024 | -$6.40M | – |
| FY2023 | Dec 31, 2023 | -$7.86M | – |
| FY2022 | Dec 31, 2022 | -$7.23M | – |
| FY2021 | Dec 31, 2021 | -$7.32M | – |
| FY2020 | Dec 31, 2020 | -$4.66M | – |
| FY2019 | Dec 31, 2019 | -$3.02M | – |
| FY2018 | Dec 31, 2018 | -$2.68M | – |
| FY2017 | Dec 31, 2017 | -$2.63M | – |
| FY2016 | Dec 31, 2016 | -$1.19M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.68M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.94M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.10M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.31M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.47M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.94M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.41M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.30M | – |
| Q2 FY2020 | Jun 30, 2020 | -$995.47K | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$668.71K | – |
| Q3 FY2019 | Sep 30, 2019 | -$613.27K | – |
| Q2 FY2019 | Jun 30, 2019 | -$739.74K | – |
| Q1 FY2019 | Mar 31, 2019 | -$995.97K | – |
| Q4 FY2018 | Dec 31, 2018 | -$519.21K | – |
| Q3 FY2018 | Sep 30, 2018 | -$599.56K | – |
| Q2 FY2018 | Jun 30, 2018 | -$752.86K | – |
| Q1 FY2018 | Mar 31, 2018 | -$808.85K | – |
| Q4 FY2017 | Dec 31, 2017 | -$816.02K | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.19M | – |
| Q2 FY2017 | Jun 30, 2017 | -$305.13K | – |
| Q1 FY2017 | Mar 31, 2017 | -$311.49K | – |
See a number that looks wrong?